Cargando…

Characterizing Binding Kinetics and Thermodynamics of Computer-Designed Nanobodies Targeting SARS-CoV-2 RBD

Detalles Bibliográficos
Autores principales:	Ferraz, Matheus, Lins, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Biophysical Society 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879881/ http://dx.doi.org/10.1016/j.bpj.2020.11.393

Ejemplares similares

Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies
por: Kaewchim, Kanasap, et al.
Publicado: (2023)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiangdong, et al.
Publicado: (2020)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiandong, et al.
Publicado: (2021)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals
por: Wu, Peng, et al.
Publicado: (2022)

A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
por: Li, Tingting, et al.
Publicado: (2021)

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
por: Lu, Qizhong, et al.
Publicado: (2021)

A Competitive Panning Method Reveals an Anti-SARS-CoV-2 Nanobody Specific for an RBD-ACE2 Binding Site
por: He, Siqi, et al.
Publicado: (2023)

Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2
por: Longsompurana, Phoomintara, et al.
Publicado: (2023)

A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-2
por: Yao, Hebang, et al.
Publicado: (2021)

Structures of synthetic nanobody–SARS-CoV-2–RBD complexes reveal distinct sites of interaction and recognition of variants
por: Ahmad, Javeed, et al.
Publicado: (2021)

Author Correction: A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection
por: Li, Tingting, et al.
Publicado: (2022)

A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System
por: Nagy-Fazekas, Dóra, et al.
Publicado: (2023)

Probing the Kinetic and Thermodynamic Fingerprints of Anti-EGF Nanobodies by Surface Plasmon Resonance
por: Guardiola, Salvador, et al.
Publicado: (2020)

Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252
por: Kaewchim, Kanasap, et al.
Publicado: (2023)

Generation and Characterization of a Nanobody Against SARS-CoV
por: Li, Jiang-Fan, et al.
Publicado: (2021)

Bionics design of affinity peptide inhibitors for SARS-CoV-2 RBD to block SARS-CoV-2 RBD-ACE2 interactions
por: Liu, Xiaofeng, et al.
Publicado: (2023)

Thermodynamic analysis of the interactions between human ACE2 and spike RBD of Betacoronaviruses (SARS‐CoV‐1 and SARS‐CoV‐2)
por: Rombel‐Bryzek, Agnieszka, et al.
Publicado: (2022)

Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering
por: Verkhivker, Gennady
Publicado: (2022)

In silico design of peptides with binding to the receptor binding domain (RBD) of the SARS-CoV-2 and their utility in bio-sensor development for SARS-CoV-2 detection
por: Badhe, Yogesh, et al.
Publicado: (2021)

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies
por: Wang, Wei Bu, et al.
Publicado: (2021)

Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding
por: Hoter, Abdullah, et al.
Publicado: (2022)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Yang, Lin, et al.
Publicado: (2021)

Cross-species binding spectrum of ACE2 to SARS-CoV-2 RBD
por: Liao, Xihao, et al.
Publicado: (2022)

Exploring the disruption of SARS-CoV-2 RBD binding to hACE2
por: Carter, Camryn, et al.
Publicado: (2023)

Targeting Ras-binding domain of ELMO1 by computational nanobody design
por: Tam, Chunlai, et al.
Publicado: (2023)

Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics
por: Barton, Michael I, et al.
Publicado: (2021)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
por: Junker, Daniel, et al.
Publicado: (2022)

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
por: Greaney, Allison J., et al.
Publicado: (2021)

Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding
por: Yang, Li Jun, et al.
Publicado: (2021)

Characterization of Critical Determinants of ACE2–SARS CoV-2 RBD Interaction
por: Brown, Emily E. F., et al.
Publicado: (2021)

Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design
por: Addala, Santhinissi, et al.
Publicado: (2022)

Therapeutische Nanobodies gegen SARS-CoV-2
por: Güttler, Thomas, et al.
Publicado: (2022)

SARS-CoV-2 nanobodies 2.0
por: Labroussaa, Fabien, et al.
Publicado: (2021)

Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response
por: Lin, Ting-Wei, et al.
Publicado: (2022)

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
por: Pymm, Phillip, et al.
Publicado: (2022)

Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease
por: Qiao, Huarui, et al.
Publicado: (2023)

Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
por: Dickey, Thayne H., et al.
Publicado: (2022)

In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine
por: Masoomi Nomandan, Seyedeh Zeinab, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_du9i03qge868ahpqbf75fs02ul